Key Points
- Director Heather Getz purchased 20,000 shares on March 16 at an average price of $0.70, raising her holdings to 131,754 shares (a 17.9% increase); the transaction was disclosed in an SEC filing.
- Analysts maintain a consensus "Buy" on MYO with an average price target of $7.67, while the stock trades near $0.72 with a market cap of about $27.8 million and a 52‑week range of $0.63–$5.62.
- Myomo is a medical robotics company that commercializes the FDA‑cleared MyoPro powered orthosis to restore mobility and function for people with upper‑limb weakness due to neuromuscular conditions.
Myomo, Inc. (NYSEAMERICAN:MYO - Get Free Report) Director Heather Getz purchased 20,000 shares of the firm's stock in a transaction that occurred on Monday, March 16th. The stock was acquired at an average price of $0.70 per share, with a total value of $14,000.00. Following the completion of the purchase, the director owned 131,754 shares in the company, valued at $92,227.80. This represents a 17.90% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Myomo Price Performance
Shares of MYO opened at $0.72 on Wednesday. Myomo, Inc. has a fifty-two week low of $0.63 and a fifty-two week high of $5.62. The firm's 50-day simple moving average is $0.83 and its two-hundred day simple moving average is $0.91. The stock has a market cap of $27.77 million, a PE ratio of -1.95 and a beta of 1.17. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.93 and a current ratio of 3.30.
Analyst Upgrades and Downgrades
MYO has been the subject of several analyst reports. Ascendiant Capital Markets reduced their price target on Myomo from $10.50 to $10.00 and set a "buy" rating for the company in a report on Friday, November 21st. Craig Hallum reiterated a "buy" rating on shares of Myomo in a research note on Tuesday, March 10th. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Myomo presently has a consensus rating of "Buy" and an average price target of $7.67.
Check Out Our Latest Stock Analysis on Myomo
Hedge Funds Weigh In On Myomo
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE grew its stake in shares of Myomo by 93.6% in the third quarter. Bank of America Corp DE now owns 30,412 shares of the company's stock worth $27,000 after acquiring an additional 14,705 shares during the period. Wells Fargo & Company MN lifted its position in Myomo by 103.1% during the fourth quarter. Wells Fargo & Company MN now owns 38,707 shares of the company's stock valued at $35,000 after purchasing an additional 19,646 shares during the period. Invesco Ltd. purchased a new stake in Myomo in the second quarter worth approximately $37,000. Intech Investment Management LLC bought a new stake in Myomo in the 2nd quarter worth approximately $38,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Myomo in the 2nd quarter worth approximately $38,000. Institutional investors own 44.99% of the company's stock.
Myomo Company Profile
(
Get Free Report)
Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company's flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users' own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.
Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
